

Prescriber Criteria Form

Retevmo 2025 PA Fax 3875-A v1 010125.docx
 Retevmo (selpercatinib)
 Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Retevmo (selpercatinib).

Drug Name:
 Retevmo (selpercatinib)

Patient Name:		
Patient ID:		
Patient DOB:	Patient Phone:	
Prescriber Name:		
Prescriber Address:		
City:	State:	Zip:
Prescriber Phone:	Prescriber Fax:	
Diagnosis:	ICD Code(s):	

Please circle the appropriate answer for each question.			
1	Does the patient have a diagnosis of rearranged during transfection (RET) fusion-positive or RET-rearrangement positive non-small cell lung cancer? [If no, then skip to question 3.]	Yes	No
2	Is the disease recurrent, advanced, or metastatic? [No further questions.]	Yes	No
3	Does the patient have a diagnosis of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC)? [If no, then skip to question 5.]	Yes	No
4	Does the patient require systemic therapy? [No further questions.]	Yes	No
5	Does the patient have a diagnosis of rearranged during transfection (RET) fusion-positive thyroid cancer (follicular, papillary, or Hurthle cell types)? [If no, then skip to question 8.]	Yes	No
6	Does the patient require systemic therapy? [If no, then no further questions.]	Yes	No
7	Does the patient meet either of the following conditions: A) treatment with radioactive iodine is appropriate for the patient and the patient is iodine-refractory, B) treatment with	Yes	No

	radioactive iodine is not appropriate for the patient? [No further questions.]		
8	Does the patient have any of the following diagnoses: A) Langerhans Cell Histiocytosis, B) symptomatic or relapsed/refractory Erdheim-Chester Disease, C) symptomatic or relapsed/refractory Rosai-Dorfman Disease, D) resectable anaplastic thyroid carcinoma? [If no, then skip to question 10.]	Yes	No
9	Does the patient have a rearranged during transfection (RET) gene fusion? [No further questions.]	Yes	No
10	Does the patient have a diagnosis of rearranged during transfection (RET) fusion-positive solid tumor? [If no, then skip to question 14.]	Yes	No
11	Is the disease recurrent, persistent, progressive, unresectable, locally advanced, or metastatic? [If no, then no further questions.]	Yes	No
12	Has the patient progressed on or following prior systemic treatment? [If yes, then no further questions.]	Yes	No
13	Does the patient have any satisfactory alternative treatment options? [No further questions.]	Yes	No
14	Does the patient have a diagnosis of brain metastases from rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)? [If yes, then no further questions.]	Yes	No
15	Does the patient have a diagnosis of rearranged during transfection (RET) fusion-positive occult primary cancer?	Yes	No

Comments:	
-----------	--

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____	Date: _____
--	--------------------